High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens

Journal of Clinical Microbiology

Volumn 43, Issue 7, 2005, Pages 3540-3543

  Peres, E ^a,b   Savasan, S ^a   Klein, J ^a   Abidi, M ^a   Dansey, R ^a   Abella, E ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; T LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALBERS SCHOENBERG DISEASE; ANTIVIRAL ACTIVITY; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; EARLY DIAGNOSIS; EPSTEIN BARR VIRUS; EX VIVO STUDY; FATALITY; FEMALE; HORSE; HUMAN; INFANT; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RISK FACTOR; SCLERODERMA; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

ADULT; ANIMALS; ANTILYMPHOCYTE SERUM; BONE MARROW TRANSPLANTATION; EPSTEIN-BARR VIRUS INFECTIONS; FATAL OUTCOME; FEMALE; HUMANS; INFANT; LYMPHOPROLIFERATIVE DISORDERS; RABBITS;

EQUIDAE; HUMAN HERPESVIRUS 4; ORYCTOLAGUS CUNICULUS;

EID: 22144475134     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.7.3540-3543.2005     Document Type: Article

References (22)

1. Chiang, K. Y., L. J. Hazlett, K. T. Godder, S. H. Abhyankar, et al. 2001. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation. Bone Marrow Transplant. 28:1117-1123.
2. Choquet, S., B. M. Mamzer, O. Hermine, et al. 2002. Identification of prognostic factors in post-transplant lymphoproliferative disorders. Recent Results Cancer Res. 159:67-80.
3. Cohen, J. I. 2000. Epstein-Barr virus infection. New Engl. J. Med. 343:481-492.
4. Dazzi, F., and J. M. Goldman. 1998. Adoptive immunotherapy following allogeneic bone marrow transplantation. Annu. Rev. Med. 49:329-340.
5. Hauke, R. J., T. C. Greiner, B. N. Smir, et al. 1998. Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases. Bone Marrow Transplant. 21:1271-1274.
6. Hoffmann, T., C. Russell, and L. Vindelov. 2002. Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation. APMIS 110:148-157.
7. Holmes, R. D., and R. J. Sokol. 2002. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr. Transplant. 6:456-464.
8. Lucas, K. G., T. N. Small, G. Heller, et al. 1996. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 87:2594-2603.
9. Micallef, I. N., M. Chhanabhai, R. D. Gascoyne, et al. 1998. Lymphoproliferative disorder following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant. 22:981-987.
10. Nash, R. A., B. R. Blazar, T. Spitzer, and M. J. Laughlin. 2002. The evolving role of equine antithymocyte globulin in hematopoietic stem cell transplantation. 2002 Tandem BMT Meeting. Blood Marrow Transplant. Rev. 12:4-14.
11. Nash, R. A., R. Dansey, J. Storek, G. E. Georges, J. D. Bowen, L. A. Holmberg, G. H. Kraft, M. D. Mayes, K. T. McDonagh, C.-S. Chen, J. DiPersio, C. F. LeMaistre, S. Pavletic, K. M. Sullivan, J. Sunderhaus, D. E. Furst, and P. A. McSweeney. 2003. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol. Blood Marrow Transplant. 9:583-591.
12. Ohga, S., A. Nomura, H. Takada, and T. Hara. 2002. Immunological aspects of Epstein-Barr virus infection. Crit. Rev. Oncol.-Hematol. 44:203-215.
13. Ohga, S., E. Kubo, A. Nomura, et al. 2001. Quantitative monitoring of circulating Epstein-Barr virus DNA for predicting the development of posttransplantation lymphoproliferative disease. Int. J. Hematol. 73:323-326.
14. Okano, M., and T. G. Gross. 2000. A review of Epstein-Barr virus infection in patients with immunodeficiency disorders. Am. J. Med. Sci. 319:392-396.
15. Orazi, A., R. A. Hromas, R. S. Neiman, et al. 1997. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am. J. Clin. Pathol. 107:419-429.
16. Perkowska, A., M. Durlik, W. Suleiman, et al. 2000. Posttransplantation lymphoproliferative disorder: case report. Transplant. Proc. 32:1387-1388.
17. Steven, N. M., N. E. Annels, A. Kumar, et al. 1997. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J. Exp. Med. 185:1605-1617.
18. Timms, J. M., A. Bell, J. R. Flavell, et al. 2003. Target cells of Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet 361:217-223.
19. van Esser, J. W. J., B. van der Holt, et al. 2001. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 98:972-978.
20. van Esser, J. W. J., H. G. Niesters, et al. 2002. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99:4364-4369.
21. Yago, K., M. Itoh, and H. Simada. 2001. Successful donor lymphocyte infusion for Epstein-Barr virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation from an HLA 1-locus-mismatched sibling donor in a patient with acute lymphocytic leukemia. Rinsho Ketsueki 42:1105-1110. (In Japanese.)
22. Zawilinska, B., K. Gruszka, B. Piatkowska-Jakubas, et al. 2001. Epstein-Barr virus infection in patients after bone marrow and heart transplantation. Przegl. Epidemiol. 55(Suppl. 3):52-55. (In Polish.)